Cure Rates of Superficial Basal Cell Carcinoma (BCC) EDC

Stopped early · Not applicable

Conditions studied: Superficial Basal Cell Carcinoma

In brief

This is a prospective, randomized clinical trial conducted at the Unviersity of Wisconsin (UW) Dermatology Clinic located at 1 S. Park Street, Madison, WI 53715. There are no controls. Subjects meeting eligibility criteria are randomly divided into one of two treatment groups (ED\&C x 1 cycle or ED\&C x 3 cycles) using computer generated random numbers. One cycle of ED\&C is defined according to standard technique currently employed. It involves scraping away the tumor with a curette (ring- shaped instrument) and then burning the curetted site with a small electric needle (electrodessication). During Visit 1, the surgical site is marked, local numbing medication is injected, and 1 or 3 cycles of ED\&C is/are performed by board-certified dermatologists or a dermatology resident under the direct supervision of a board certified dermatologist. All follow-up visits (3, 6, 9, and 12 months after Visit 1) include skin evaluations by the physician who performed the ED\&C. The lesion site is examined, measured, and photographed for clinical evidence of recurrence, as defined by a new lesion within the previously treated site. If there is evidence of possible tumor recurrence at the treated surgical site during Visit 2, 3, 4 or 5, then the lesion will be biopsied using a shave procedure.

Key facts

Study ID

NCT00994240

Run by

University of Wisconsin, Madison

People needed

85

Starts

2008-05-01

Expected to finish

2013-09-01

Last updated by the study team

2015-02-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Untreated, biopsy proven superficial type basal cell carcinoma (BCC-S) on the trunk and/or extremities
• Age greater than 21
• Women with childbearing potential (including those who are pregnant/lactating)
• Able to provide written informed consent

You may not qualify if…

• Aggressive histology on initial biopsy (i.e. morpheaform, infiltrative, desmoplastic, or purely micronodular)
• Prior history of BCC or other skin cancer at the same location
• Lesion > 2 cm
• Patients with basal cell nevus syndrome
• Transplant patients
• Immunocompromised patients
• Recurrent BCC
• Greater than 2 BCC-S on the trunk and/or extremities
• Prisoners
• Allergy to lidocaine or epinephrine

Where it is running

• University of Wisconsin-Madison, Department of Dermatology — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.